Segment Disclosure

12 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Segment Disclosure

Note 17. Segment Disclosure

The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset based metrics. Therefore, the information below is presented only for revenues and long‑lived tangible assets by geographic areas.

Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):

	Years ended June 30,
	2020		2019		2018
Americas	$	128,562	$	135,683	$	145,689
Europe, Middle East, India and Africa		119,989		149,095		120,032
Asia Pacific (excluding Japan and India)		61,689		63,793		72,925
Japan		72,688		70,214		66,251
Total	$	382,928	$	418,785	$	404,897

Information regarding geographic areas in which the Company has long‑lived tangible assets is as follows (in thousands):

	June 30, 2020		June 30, 2019
Americas	$	12,807	$	13,853
Europe, Middle East, India and Africa		373		575
Asia Pacific (excluding Japan and India)		986		1,419
Japan		1,183		1,275
Total	$	15,349	$	17,122